ADARx Pharmaceuticals: SR One entities buy 1.6M shares
The three common-stock purchases were each priced at $17 per share; the preferred-stock conversions required no further consideration.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ADARx Pharmaceuticals, Inc. had indirect preferred-stock conversions reported by SR One Capital Management, LLC, a ten percent owner. The preferred securities were directly held by SR One Capital Fund I Aggregator, LP, SR One Capital Opportunities Fund I, LP and SR One Co-Invest III, LLC; upon ADARx’s IPO closing on September 28, 2026, they automatically converted into common stock on a 1-for-1.1717 reverse stock split basis, without further consideration. Separately, SR One Capital Fund I Aggregator, LP purchased 592,593 shares, SR One Capital Opportunities Fund I, LP purchased 414,814 shares and AMZL, LP purchased 592,593 shares, each at $17 per share. AMZL held 592,593 shares after its purchase. No Rule 10b5-1 plan is reported.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 1,600,000 shares
Net Buy
15 txns
Insider
SR ONE CAPITAL MANAGEMENT, LLC
Role
10% Owner
Bought
1,600,000 shs ($27.20M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock F1, F2 | 3,907,547 | $0.00 | $0.00 |
| Conversion | Series B-1 Preferred Stock F1, F2 | 1,304,883 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock F1, F2 | 600,962 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock F1, F3 | 1,802,885 | $0.00 | $0.00 |
| Conversion | Series B Preferred Stock F1, F4 | 1,953,773 | $0.00 | $0.00 |
| Conversion | Series B-1 Preferred Stock F1, F4 | 198,019 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F2 | 3,334,938 | -- | -- |
| Conversion | Common Stock F1, F2 | 1,113,666 | -- | -- |
| Conversion | Common Stock F1, F2 | 512,897 | -- | -- |
| Purchase | Common Stock F2 | 592,593 | $17.00 | $10.07M |
| Conversion | Common Stock F1, F3 | 1,538,691 | -- | -- |
| Purchase | Common Stock F3 | 414,814 | $17.00 | $7.05M |
| Conversion | Common Stock F1, F4 | 1,667,468 | -- | -- |
| Conversion | Common Stock F1, F4 | 169,001 | -- | -- |
| Purchase | Common Stock F5 | 592,593 | $17.00 | $10.07M |
Holdings After Transaction:
Series B Preferred Stock — 0 contracts (Indirect, See Note 2);
Series B-1 Preferred Stock — 0 contracts (Indirect, See Note 2);
Series C Preferred Stock — 0 contracts (Indirect, See Note 2);
Series C Preferred Stock — 0 contracts (Indirect, See Note 3);
Series B Preferred Stock — 0 contracts (Indirect, See Note 4);
Series B-1 Preferred Stock — 0 contracts (Indirect, See Note 4);
Common Stock — 5,554,094 shares (Indirect, See Note 2);
Common Stock — 1,953,505 shares (Indirect, See Note 3);
Common Stock — 1,836,469 shares (Indirect, See Note 4);
Common Stock — 592,593 shares (Indirect, See Note 5)
Footnotes (5)
- F1. Each share of Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 reverse stock split basis into shares of Common Stock upon the closing of the Issuer's initial public offering on September 28, 2026, without payment of further consideration. The Preferred Stock has no expiration date.
- F2. The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- F3. The securities are directly held by SR One Capital Opportunities Fund I, LP ("SR One Opportunities Fund I"). SR One Capital Opportunities Partners I, LP ("SR One Opportunities Partners I") is the sole general partner of SR One Opportunities Fund I, and SR One Capital Management is the sole general partner of SR One Opportunities Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Opportunities Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- F4. The securities are directly held by SR One Co-Invest III, LLC ("SR One Co-Invest"). SR One Co-Invest III Manager LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- F5. The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
Key Figures
Common shares purchased: 1,600,000 shares
Purchase price: $17 per share
Common shares received on Series B conversion: 3,334,938 shares
+5 more
8 metrics
Common shares purchased
1,600,000 shares
Three indirect purchases on September 28, 2026
Purchase price
$17 per share
Price for the three common-stock purchases
Common shares received on Series B conversion
3,334,938 shares
Held by SR One Capital Fund I Aggregator, LP
Common shares received on Series B-1 conversion
1,113,666 shares
Held by SR One Capital Fund I Aggregator, LP
Common shares received on Series C conversion
512,897 shares
Held by SR One Capital Fund I Aggregator, LP
Common shares received on Series C conversion
1,538,691 shares
Held by SR One Capital Opportunities Fund I, LP
Common shares received on Series B conversion
1,667,468 shares
Held by SR One Co-Invest III, LLC
Common shares received on Series B-1 conversion
169,001 shares
Held by SR One Co-Invest III, LLC
Key Terms
reverse stock split basis, without payment of further consideration, beneficial ownership, pecuniary interest
4 terms
reverse stock split basis financial
"converted on a 1-for-1.1717 reverse stock split basis"
without payment of further consideration financial
"without payment of further consideration"
beneficial ownership regulatory
"disclaims beneficial ownership of the shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of any pecuniary interest therein"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did the ADRX preferred-stock conversion work?
Series B, Series B-1 and Series C preferred shares automatically converted into common stock on a 1-for-1.1717 reverse stock split basis when ADARx’s IPO closed on September 28, 2026, without payment of further consideration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
